Positive results from Auxilium Pharmaceuticals' XIAFLEX Peyronie's disease phase IIb trial

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced top-line efficacy and safety results for the phase IIb clinical trial for XIAFLEX™ (collagenase clostridium histolyticum) in the treatment of Peyronie's disease. The phase IIb study was designed to measure efficacy endpoints of improvement in penile curvature and improvement in patients' sexual quality of life using the Company's Peyronie's disease Patient Reported Outcome (PRO) questionnaire. Overall, XIAFLEX demonstrated a statistically significant change compared to placebo at 36 weeks in both improvement in penile curvatures disease bother domains disease trials with XIAFLEX, which included injection site bruising, edema and pain.

"We believe the results from this trial provide a meaningful step forward to a better understanding of the treatment of Peyronie's disease with XIAFLEX," said Armando Anido, Auxilium's Chief Executive Officer and President. "We expect to meet with the FDA in the second quarter of 2010 to discuss a proposed phase III plan that potentially could be started in the second half of 2010."

SOURCE: Auxilium Pharmaceuticals, Inc.

Comments

  1. donald drechsler donald drechsler United States says:

    I am one of those with both Peyronies and dupuytrens. I was one of the first to get treated for dupuytrens after xiaflex was approved. It worked better than I could ever hope for. Also I had only one treatment
    and now have no signs that I ever had dupuytrens. So I hope they finish their test soon and allow us to get treated peyronies fast as this much more troublesome than dupuytrens.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI outperforms doctors in diagnostics but falls short as a clinical assistant